<DOC>
	<DOCNO>NCT01460888</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dose ( MTD ) olaparib combination radical radiotherapy patient oesophageal cancer unsuitable platinum contain chemotherapy .</brief_summary>
	<brief_title>Radiotherapy &amp; Olaparib COmbination Carcinoma Oesophagus</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma squamous cell carcinoma oesophagus include Siewert type 1 2 tumour ≤2cm gastric mucosal extension 2 . Unsuitable radical chemoradiation therapy suitable radiotherapy 3 . Total length tumour involve lymph node ≤10cm 4 . No oesophageal stent situ 5 . No previous chemotherapy radiotherapy oesophagus cancer 6 . Disease encompass within radical radiotherapy treatment volume 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( see ECOG criterion appendix 1 ) 8 . Provision fully inform consent , sign , write date , prior study specific procedure . 9 . &gt; 18 year age . 10 . Adequate organ bone marrow function measure within 28 day prior administration study treatment define : Haemoglobin ≥ 10.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L White blood cell ( WBC ) &gt; 3 x 109/L Platelet count ≥ 100 x 109/L No dysplastic feature peripheral blood smear Total bilirubin ≤ 1.5 x institutional upper limit normal Aspartate aminotransferase ( AST ( SGOT ) /Alanine transaminase ( ALT ) SGPT ) ≤ 2.5 x institutional upper limit normal Serum creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) 11 . Adequate lung function : history interstitial lung disease FEV1 &gt; 1litre &gt; 30 % predict . 12 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment day 1 . Postmenopausal define : Amenorrheic 1 year follow cessation exogenous hormonal treatment Luteinizing hormone ( LH ) Folliclestimulating hormone ( FSH ) level post menopausal range woman 50 , radiationinduced oophorectomy last menses &gt; 1 year ago , chemotherapyinduced menopause &gt; 1 year interval since last menses , surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 13 . Patient willing able comply protocol duration study include undergoing treatment schedule visit examination . 14 . Fit receive study treatment 15 . Swallowing sufficiently good tolerate oral medication 16 . Life expectancy ≥ 4 month . 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) 2 . Previous enrolment present study 3 . Treatment investigational product last 14 day ( long period depend defined characteristic agent use ) 4 . Any previous treatment poly adenosine diphosphateribose polymerase ( PARP ) inhibitor , include olaparib . 5 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≥ 5 year . 6 . Patients receive follow class inhibitor cytochrome P450 3A4 ( CYP3A4 ) Azole antifungal Macrolide antibiotic Protease inhibitor 7 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 8 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , psychiatric disorder prohibits obtain informed consent . 9 . Patients history interstitial lung disease , inflammatory lung condition , severe chronic obstructive pulmonary disease ( COPD ) ( FEV1 &lt; 1litre &lt; 30 % predict ) . Patients pneumonia within previous 3 month . 10 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . 11 . Patients oesophageal stent insitu 12 . Patients myelodysplastic syndrome/acute myeloid leukaemia 13 . Immunocompromised patient , e.g. , patient know serologically positive human immunodeficiency virus ( HIV ) . 14 . Patients know active hepatic disease ( i.e. , Hepatitis B C ) . 15 . Patients know hypersensitivity olaparib excipients product . 16 . Patients uncontrolled seizure . 17 . Concurrent uncontrolled medical illness , previous current malignant disease likely interfere protocol treatment / comparison 18 . Age &lt; 18 19 . Any pregnant , lactate woman potentially childbearing patient use adequate contraception ( see section 3.4 detail require contraception ) . 20 . Previous chemotherapy radiotherapy oesophageal cancer 21 . Metastatic disease apart local lymph node disease reasonably encompass within radiotherapy volume ( total length tumour lymph node disease &lt; 10cm ) 22 . ECOG performance status &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>